Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentation at the 18th Annual NewsMakers in the Biotech Industry Conference
WALTHAM, Mass., Oct. 13, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc . (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that its presentation at the 18 th Annual NewsMakers in the Biotech Industry conference at 10:30 am ET on October 21,
Toggle Summary T-DM1 Significantly Improved Progression-Free Survival Compared to Standard of Care for Previously Untreated HER2-Positive Metastatic Breast Cancer
Notable results from Genentech/Roche Phase II trial are featured in conference's official press program T-DM1 utilizes ImmunoGen's Targeted Antibody Payload (TAP) technology with the HER2-targeting trastuzumab (Herceptin(R)) antibody